Subsidiary Aprogen Biologics Issues 50.8 Billion Won CB with Discounted Conversion Price, Combined with Existing CBs to Create 262% Dilution Risk
Aprogen's subsidiary Aprogen Biologics decided to issue 50.8 billion won in 20th series unsecured private convertible bonds (CB)
Conversion price set at 3,778 won, approximately 10.3% discount from the previous day's closing price of 4,210 won, with a minimum adjusted price of 2,645 won
Proceeds entirely used to repay borrowings from affiliate Aptochrom (debt repayment of 50.8 billion won), not for facility investment or operating funds
Combining existing outstanding CBs (4 issues, balance 128 billion won) with new CB, total convertible shares reach 37,873,359, representing 262.78% of current outstanding shares of 14,412,374, indicating extreme dilution potential
Conversion period from June 4, 2027 to May 4, 2029, with put option exercisable from December 4, 2027
CB subscriber is affiliate Aptochrom, and payment is made by offsetting receivables from Aptochrom
[AI Comprehensive Analysis]This CB issuance is a negative event that can significantly impair shareholder value due to the discounted conversion price and massive dilution when combined with existing CBs. The funds are used merely for debt repayment without productive investment, failing to create growth momentum. Upon conversion, the overhang will likely exert considerable downward pressure on the stock price.
KOSPI Filing Information
Filing: Major Event Report (Decision on Issuance of Convertible Bonds) (Major Management Matters of Subsidiary)